Does Paroxysmal Kinesigenic Choreathetosis / Dyskinesia have a cure?

Currently, there is no permanent cure for Paroxysmal Kinesigenic Choreathetosis (PKC), also known as Paroxysmal Kinesigenic Dyskinesia (PKD). However, the condition is highly treatable, and most patients achieve complete or near-complete remission of symptoms through pharmacological management.

Is there a cure for Paroxysmal Kinesigenic Dyskinesia?

While we do not yet have a curative therapy that permanently alters the underlying neurobiology of Paroxysmal Kinesigenic Choreathetosis, the condition is exceptionally responsive to medication. For many individuals, daily treatment allows them to live symptom-free, effectively managing the involuntary movements triggered by sudden motion.

How are symptoms of Paroxysmal Kinesigenic Choreathetosis managed?

Treatment for Paroxysmal Kinesigenic Dyskinesia focuses on stabilizing the neuronal excitability that causes these sudden episodes. Physicians typically prescribe low-dose anticonvulsants, which are often highly effective. Common management strategies include:

• Anticonvulsant therapy: Carbamazepine or oxcarbazepine are considered the gold-standard treatments, often providing total control of attacks at low doses.


• Alternative medications: For those who do not tolerate standard therapies, options like lacosamide, phenytoin, or topiramate may be explored.


• Trigger avoidance: Identifying and managing specific physical triggers—such as sudden movements or startle responses—can help reduce the frequency of breakthrough episodes.

What does the future of research hold for PKC?

Research into Paroxysmal Kinesigenic Choreathetosis has advanced significantly since the discovery of the PRRT2 gene mutation in 2011. Because the genetic mechanism is well-understood, scientists are focusing on precision medicine. Current research is investigating how PRRT2 deficiency affects synaptic vesicle docking and neurotransmitter release. While gene therapy is not yet in human trials for this condition, the clarity of the genetic cause makes it a prime candidate for future molecular interventions.

Next steps

• Consult a neurologist specializing in movement disorders to optimize your medication regimen.


• Connect with the 7 members of the DiseaseMaps.org community who are navigating life with Paroxysmal Kinesigenic Choreathetosis.


• Monitor ClinicalTrials.gov for updates on new pharmacological trials or observational studies.


• Keep a detailed diary of your triggers and medication response to share during clinical visits.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Paroxysmal Kinesigenic Dyskinesia.


• Orphanet: Paroxysmal kinesigenic choreoathetosis (ORPHA:1878).


• OMIM (Online Mendelian Inheritance in Man): Dyskinesia, familial kinesigenic, 1 (Entry #128200).


• PubMed: "PRRT2-associated paroxysmal kinesigenic dyskinesia: an update on clinical and genetic aspects."